NDRM - NeuroDerm Ltd.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

NeuroDerm Ltd.

Ruhrberg Science Building
3 Pekeris Street
Rehovot 7670212
972 8 946 2729

Full Time Employees55

Key Executives

Mr. Oded S. Lieberman Ph.D., MBAN/AN/A59
Mr. Roy Golan CPA, LLMN/AN/A44
Dr. Oron Yacoby-Zeevi Ph.D., DVMN/AN/A56
Dr. Sheila Oren M.D., MBAN/AN/A55
Dr. Sharon Cohen-Vered Ph.D.275.85kN/A51
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NeuroDerm Ltd., a clinical-stage pharmaceutical company, engages in developing drug-device combinations for the treatment of central nervous system (CNS) disorders. The company’s levodopa and carbidopa (LD/CD) product candidates, which have completed Phase IIa clinical trial, include ND0612L and ND0612H for the treatment of patients with moderate and advanced Parkinson’s disease. It is also developing ND0701, a subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD; and ND0801, which is in Phase IIa clinical trial for the treatment of cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimer’s disease, and schizophrenia. NeuroDerm Ltd. was founded in 2003 and is headquartered in Rehovot, Israel.

Corporate Governance

NeuroDerm Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.